Lba41 - Leap-005: Phase Ii Study Of Lenvatinib Plus Pembrolizumab

LBA41 - LEAP-005: Phase II study of lenvatinib plus pembrolizumab

ESMO 2020 Highlights on lenvatinib plus pembrolizumab in advanced solid tumours: LEAP-005

European Society for Medical Oncology (ESMO)

Promising results from the gastric cancer cohort of LEAP-005

Dr. Lwin on the Results of the LEAP-005 Trial in Advanced Solid Tumors

LEAP-015: lenvatinib + pembrolizumab + mFOLFOX6 in advanced/met gastroesophageal adenocarcinoma

Lenvatinib plus pembrolizumab for advanced melanoma that progressed on a PD-1 or PD-L1 inhibitor...

Treating patients with melanoma who progressed on anti-PD-L1 with lenvatinib and pembrolizumab

Dr. Makker on Safety Signals With Lenvatinib and Pembrolizumab in Endometrial Cancer

LBA44 - Lenvatinib plus pembrolizumab for advanced melanoma

NeoPeLe: neoadjuvant pembrolizumab and lenvatinib in resectable stage III melanoma

#ESMO19: Lenvatinib (LEN) and Pembrolizumab (PEMBRO) in Advanced Endometrial Cancer

Society of Gynecologic Oncology

KEYSTEP-004: combination immunotherapy with lenvatinib for advanced HCC

KEYNOTE-057 update: pembrolizumab for high-risk NMIBC patients

KEYNOTE-775 subgroup analysis in advanced endometrial cancer

Dr. Tolaney on Abemaciclib Plus Pembrolizumab for HR+, HER2- Breast Cancer

Study of Nab-Paclitaxel with Pembrolizumab for Patients with HR+/HER2- Breast Cancer

Dana-Farber Cancer Institute

Evaluating Second-Line Treatment Options in Bladder Cancer

Targeted Oncology

Dr. Zamarin on the Role of Pembrolizumab in Endometrial Cancer

Olea Nova Move - Dynamic temporal information of blood flow

Sequencing endocrine treatment in metastatic luminal breast cancer and alpelisib for treatment o...